Denali Therapeutics Inc (DNLI) — Cash Flow-to-Debt Ratio
Denali Therapeutics Inc (DNLI) has a Cash Flow-to-Debt Ratio of -0.83x as of September 2025, meaning its operating cash flow of $-107.30 Million could theoretically repay -1% of its total liabilities ($129.42 Million) in one year. See how much free cash does Denali Therapeutics Inc generate to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Denali Therapeutics Inc Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Denali Therapeutics Inc across 10 annual periods. Also explore how fast is Denali Therapeutics Inc growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Denali Therapeutics Inc (2015–2024)
Year-by-year debt coverage analysis for Denali Therapeutics Inc. For market capitalisation and broader financial context, see DNLI market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.41x | $-347.69 Million | $144.50 Million | ▲ +17.3% |
| 2023 | -2.91x | $-357.99 Million | $122.96 Million | ▼ -397.1% |
| 2022 | -0.59x | $-244.72 Million | $417.81 Million | ▼ -22.4% |
| 2021 | -0.48x | $-211.39 Million | $441.87 Million | ▼ -152.2% |
| 2020 | 0.92x | $416.15 Million | $453.75 Million | ▲ +195.8% |
| 2019 | -0.96x | $-151.58 Million | $158.34 Million | ▼ -319.9% |
| 2018 | 0.44x | $50.12 Million | $115.14 Million | ▲ +111.9% |
| 2017 | -3.66x | $-76.64 Million | $20.93 Million | ▲ +16.2% |
| 2016 | -4.37x | $-72.36 Million | $16.55 Million | ▼ -1419.8% |
| 2015 | -0.29x | $-15.05 Million | $52.32 Million | — |